Integration of Genomic and Clinical Trial Data Enables Biomarker Hypothesis Generation by Clinical Development
For the second consecutive year, Medidata (NASDAQ:MDSO) will be presenting its pioneering analytics innovation during the 2018 ASCO Annual Meeting. The hour-long “Industry Expert Theater” session*, Integration of Genomics Data and Analysis in Oncology Research, will occur on June 2 at 9:30 AM CDT at the Oncology Professionals Hall, McCormick Place Convention Center in Chicago.
Medidata experts will showcase the value of Medidata Rave Omics with Biomarker Discovery in Oncology:
Speakers:
About Medidata
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com
*The “Industry Expert Theater Presentation” is a series of hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies. Not an official presentation of the meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation. Not CME-accredited.
View source version on businesswire.com:
Investors:
Medidata Solutions
Betsy Frank, +1-917-522-4620
bfrank@mdsol.com
or
Media:
Medidata
Solutions
Erik Snider, +1-646-362-2997
esnider@mdsol.com